CENTERPIECE BIO
Innovating the Future of Regenerative Medicine
Introduction to Centerpiece Bio
Centerpiece Bio is a pioneer in the biotechnology industry, having developed Korea's first serum-free stem cell culture medium[cite: 33, 93]. Our mission is to lead the localization of essential bio-materials and supply high-quality culture media to the global market[cite: 93, 230].
- Developed chemically defined stem cell culture fluids to overcome the harmfulness and instability of fetal bovine serum (FBS)[cite: 43, 244].
- Focusing on high-tech regenerative biopharmaceutical markets and fast-track commercialization[cite: 231].
- Committed to solving ethical and biological issues associated with animal-derived serums[cite: 300, 316].
Organizational Structure
Our company is strategically organized into three core business groups to maximize synergy between research and commercial application.
Bio Tech Unit
Responsible for R&D, QC, and the production of stem cell (SC) and NK cell culture media[cite: 66, 71, 74].
Healthcare Unit
Focuses on clinical application, patient management, and specialized cell therapy centers[cite: 78, 858, 859].
Cosmetics Unit
Utilizes stem cell culture technology to develop advanced functional skincare and brand designs[cite: 49, 55, 63].
Technology and Patents
Patent No. 10-2021-0008888
Title: Development of chemically defined stem cell culture fluid to overcome the harmfulness of fetal serum components[cite: 42, 43].
Our patented technology enables the cultivation of fat-derived stem cells without animal-derived serum, ensuring high safety and stability[cite: 261, 265, 292].
Key Technical Advantages:
- Excellent cell differentiation rates and retention of stem cell properties[cite: 267, 321].
- International standard GMP grade culture with a failure rate of approximately 0%[cite: 306].
- Solidified technical barriers through registered patents (No. 10-2296986)[cite: 239, 296].
Global Strategy
Centerpiece Bio is expanding its footprint through a sophisticated B2B supply chain and automated production platforms[cite: 93, 103].
- B2B Network: Annual supply contracts with domestic and global bio companies for R&D and raw materials[cite: 93, 103].
- Smart Factory: Establishing NK cell anti-cancer platforms through Global Bio Smart Factory automation.
- Localization: Solving material supply issues caused by foreign monopolies and trade regulations[cite: 230, 307].
- OEM/ODM: Capable of consignment production through global GMP-grade facilities[cite: 102, 103].